Depreciation, Depletion and Amortization in USD of ARROWHEAD PHARMACEUTICALS, INC. from 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Summary
ARROWHEAD PHARMACEUTICALS, INC. quarterly/annual Depreciation, Depletion and Amortization history and change rate from 2010 to Q3 2025.
  • ARROWHEAD PHARMACEUTICALS, INC. Depreciation, Depletion and Amortization for the quarter ending 30 Sep 2025 was $6M, a 30.4% increase year-over-year.
  • ARROWHEAD PHARMACEUTICALS, INC. Depreciation, Depletion and Amortization for the twelve months ending 30 Sep 2025 was $22.2M, a 31.4% increase year-over-year.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Depreciation, Depletion and Amortization for 2025 was $22.2M, a 31.4% increase from 2024.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Depreciation, Depletion and Amortization for 2024 was $16.9M, a 57.9% increase from 2023.
  • ARROWHEAD PHARMACEUTICALS, INC. annual Depreciation, Depletion and Amortization for 2023 was $10.7M, a 23% increase from 2022.
Depreciation, Depletion and Amortization, Trailing 12 Months (USD)
Depreciation, Depletion and Amortization, Quarterly (USD)
Depreciation, Depletion and Amortization, YoY Quarterly Change (%)
Depreciation, Depletion and Amortization, Annual (USD)
Depreciation, Depletion and Amortization, YoY Annual Change (%)

ARROWHEAD PHARMACEUTICALS, INC. Quarterly Depreciation, Depletion and Amortization (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $22.2M $6M +$1.4M +30.4% 01 Jul 2025 30 Sep 2025 10-K 25 Nov 2025
Q2 2025 $20.8M $5.8M +$1.4M +31.8% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 $19.4M $5.6M +$1.5M +36.6% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025
Q4 2024 $17.9M $4.8M +$1M +26.3% 01 Oct 2024 31 Dec 2024 10-Q 10 Feb 2025
Q3 2024 $16.9M $4.6M +$1.3M +39.4% 01 Jul 2024 30 Sep 2024 10-K 25 Nov 2025
Q2 2024 $15.6M $4.4M +$1.5M +51.7% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 $14.1M $4.1M +$1.9M +86.4% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025
Q4 2023 $12.2M $3.8M +$1.5M +65.2% 01 Oct 2023 31 Dec 2023 10-Q 10 Feb 2025
Q3 2023 $10.7M $3.3M +$1.1M +50% 01 Jul 2023 30 Sep 2023 10-K 25 Nov 2025
Q2 2023 $9.6M $2.9M +$700K +31.8% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 $8.9M $2.2M $0 0% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024
Q4 2022 $8.9M $2.3M +$200K +9.52% 01 Oct 2022 31 Dec 2022 10-Q 06 Feb 2024
Q3 2022 $8.7M $2.2M +$100K +4.76% 01 Jul 2022 30 Sep 2022 10-K 26 Nov 2024
Q2 2022 $8.6M $2.2M +$600K +37.5% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023
Q1 2022 $8M $2.2M +$700K +46.7% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023
Q4 2021 $7.3M $2.1M +$700K +50% 01 Oct 2021 31 Dec 2021 10-Q 06 Feb 2023
Q3 2021 $6.6M $2.1M +$700K +50% 01 Jul 2021 30 Sep 2021 10-K 29 Nov 2023
Q2 2021 $5.9M $1.6M +$500K +45.5% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022
Q1 2021 $5.4M $1.5M +$600K +66.7% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022
Q4 2020 $4.8M $1.4M +$600K +75% 01 Oct 2020 31 Dec 2020 10-Q 02 Feb 2022
Q3 2020 $4.2M $1.4M +$781K +126% 01 Jul 2020 30 Sep 2020 10-K 28 Nov 2022
Q2 2020 $3.42M $1.1M +$522K +90.2% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021
Q1 2020 $2.9M $900K +$149K +19.9% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021
Q4 2019 $2.75M $800K +$47.8K +6.35% 01 Oct 2019 31 Dec 2019 10-Q 04 Feb 2021
Q3 2019 $2.7M $619K 01 Jul 2019 30 Sep 2019 10-K 22 Nov 2021
Q2 2019 $578K 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020
Q1 2019 $751K 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020
Q4 2018 $752K 01 Oct 2018 31 Dec 2018 10-Q 05 Feb 2020
Q3 2014 $1.35M $270K -$129K -32.2% 01 Jul 2014 30 Sep 2014 10-K 25 Nov 2014
Q2 2014 $1.47M $276K -$178K -39.2% 01 Apr 2014 30 Jun 2014 10-Q 12 Aug 2014
Q1 2014 $1.65M $396K -$53K -11.8% 01 Jan 2014 31 Mar 2014 10-Q 06 May 2014
Q4 2013 $1.71M $403K -$46.2K -10.3% 01 Oct 2013 31 Dec 2013 10-Q 04 Feb 2014
Q3 2013 $1.75M $399K -$48.2K -10.8% 01 Jul 2013 30 Sep 2013 10-K 25 Nov 2014
Q2 2013 $1.8M $454K +$30.7K +7.24% 01 Apr 2013 30 Jun 2013 10-Q 12 Aug 2014
Q1 2013 $1.77M $449K +$24.8K +5.85% 01 Jan 2013 31 Mar 2013 10-Q 06 May 2014
Q4 2012 $1.74M $450K -$4.85K -1.07% 01 Oct 2012 31 Dec 2012 10-Q 04 Feb 2014
Q3 2012 $1.75M $447K +$382K +589% 01 Jul 2012 30 Sep 2012 10-K 25 Nov 2014
Q2 2012 $1.37M $423K +$357K +537% 01 Apr 2012 30 Jun 2012 10-Q 07 Aug 2013
Q1 2012 $1.01M $424K +$356K +525% 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013
Q4 2011 $654K $454K +$386K +561% 01 Oct 2011 31 Dec 2011 10-Q 13 Feb 2013
Q3 2011 $268K $64.9K 01 Jul 2011 30 Sep 2011 10-K 28 Dec 2012
Q2 2011 $66.5K 01 Apr 2011 30 Jun 2011 10-Q 13 Aug 2012
Q1 2011 $67.8K 01 Jan 2011 31 Mar 2011 10-Q 08 May 2012
Q4 2010 $68.8K 01 Oct 2010 31 Dec 2010 10-Q 09 Feb 2012

ARROWHEAD PHARMACEUTICALS, INC. Annual Depreciation, Depletion and Amortization (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2025 $22.2M +$5.3M +31.4% 01 Oct 2024 30 Sep 2025 10-K 25 Nov 2025
2024 $16.9M +$6.2M +57.9% 01 Oct 2023 30 Sep 2024 10-K 25 Nov 2025
2023 $10.7M +$2M +23% 01 Oct 2022 30 Sep 2023 10-K 25 Nov 2025
2022 $8.7M +$2.1M +31.8% 01 Oct 2021 30 Sep 2022 10-K 26 Nov 2024
2021 $6.6M +$2.4M +57.1% 01 Oct 2020 30 Sep 2021 10-K 29 Nov 2023
2020 $4.2M +$1.5M +55.6% 01 Oct 2019 30 Sep 2020 10-K 28 Nov 2022
2019 $2.7M -$299K -9.97% 01 Oct 2018 30 Sep 2019 10-K 22 Nov 2021
2018 $3M +$8.84K +0.3% 01 Oct 2017 30 Sep 2018 10-K 23 Nov 2020
2017 $2.99M 01 Oct 2016 30 Sep 2017 10-K 25 Nov 2019
2014 $1.35M -$406K -23.2% 01 Oct 2013 30 Sep 2014 10-K 25 Nov 2014
2013 $1.75M +$2.44K +0.14% 01 Oct 2012 30 Sep 2013 10-K 25 Nov 2014
2012 $1.75M +$1.48M +553% 01 Oct 2011 30 Sep 2012 10-K 25 Nov 2014
2011 $268K -$9.67K -3.48% 01 Oct 2010 30 Sep 2011 10-K 28 Dec 2012
2010 $278K 01 Oct 2009 30 Sep 2010 10-K 20 Dec 2011
* An asterisk sign (*) next to the value indicates that the value is likely invalid.